Health Care Initiatives, Clinical Data Presentations, Public Offerings, Contract Extensions and Publication of Pre-Clinical Study - Research Report on Cigna, Arena, Synta, Healthways, and Catalyst Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, November 21, 2013 NEW YORK, November 21, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Cigna Corp. (NYSE: CI), Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), Synta Pharmaceuticals Corp. (NASDAQ: SNTA), Healthways Inc. (NASDAQ: HWAY), and Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Cigna Corp. Research Report On November 18, 2013, Cigna Corp. (Cigna) announced that it has launched a collaborative accountable care initiative with University Hospitals Accountable Care Organization (UHACO). According to the Company, the program aims to enhance care coordination and achieve the "triple aim" of improved health, affordability and patient experience for Cigna customers. According to the Company, the program will benefit approximately 10,000 people covered by a Cigna health plan who receive care from the 1,500 primary care physicians and specialists employed by University Hospitals (UH) in the Cleveland area. "We need a patient-centered health care system that emphasizes prevention and primary care and rewards physicians for quality of care and improved health outcomes," said Julia Huggins, President of Cigna in Ohio. "A system that's focused on value rather than volume will ultimately lead to a healthier population and lower medical costs, which is good for individuals, families, employers and doctors." The Full Research Report on Cigna Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/7307_CI Arena Pharmaceuticals, Inc. Research Report On November 18, 2013, Arena Pharmaceuticals, Inc. (Arena) and Eisai Inc. jointly announced the presentation of a new data analysis from the BELVIQ® (lorcaserin HCl) Phase 3 clinical trial program at the American Heart Association 2013 Scientific Sessions, to be held from November 16-20, 2013 in Dallas, Texas. According to the Company, the abstract 'the Effects of Lorcaserin on High-Sensitivity C-reactive Protein in Overweight and Obese Patients: Data From Two Phase 3 Trials' will highlight the data presentation on BELVIQ, which is believed to decrease food consumption and promote satiety by selectively activating serotonin 2C receptors in the brain. The Full Research Report on Arena Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/6a95_ARNA Synta Pharmaceuticals Corp. Research Report On November 18, 2013, Synta Pharmaceuticals Corp. (Synta) announced the closing of its underwritten public offering of 16.1 million shares of common stock, including 2.1 million shares sold in pursuant to the full exercise of the underwriters' option to purchase additional shares, at a public offering price of $3.75 per share. The Company informed that gross proceeds to Synta from the offering are c.$60.4 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Synta. The Company further informed that Jefferies LLC acted as the sole book-running manager for the offering, while JMP Securities, Brean Capital, LLC and Roth Capital Partners acted as co-managers for the same. The Full Research Report on Synta Pharmaceuticals Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/8ecc_SNTA Healthways Inc. Research Report On November 12, 2013, Healthways Inc. (Healthways) announced the extension of its current contract offering its nationally acclaimed SilverSneakers® Fitness Program to eligible Independence Blue Cross (IBC) members throughout Pennsylvania, until 2014. "Independence Blue Cross is committed to exceeding customers' expectations through the provision of innovative health and wellness solutions like the SilverSneakers Fitness Program," said Ben R. Leedle, Jr., Healthways' President and CEO. "By focusing on increased access to quality health care and delivering value through its products and services, IBC is demonstrating its commitment to their older adult members, with a user-friendly, proven program that offers a unique combination of physical fitness and essential social experiences." The Full Research Report on Healthways Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/76fd_HWAY Catalyst Pharmaceutical Partners Inc. Research Report On November 18, 2013, Catalyst Pharmaceuticals Partners, Inc. (Catalyst) announced that the journal Epilepsia has accepted for publication of preclinical proof-of-principle of CPP-115 efficacy in suppressing infantile spasms (IS). According to the Catalyst, CPP-115 is a next-generation GABA aminotransferase inhibitor being developed for the treatment of IS. "There is a significant unmet medical need in this area, as parents of children who have infantile spasms have a very difficult choice when it comes to treatment options, as they must choose between drug-related risks and adequate treatment," said Patrick J. McEnany, Chairman and CEO of Catalyst. The Company further informed that it plans to initiate a Phase I multiple-dose ascending study in the first half of 2014 to evaluate the safety and tolerability of multiple ascending oral doses of CPP-115. The Full Research Report on Catalyst Pharmaceutical Partners Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/a791_CPRX EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. http://www.analystscorner.com/ SOURCE Analysts' Corner Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
Health Care Initiatives, Clinical Data Presentations, Public Offerings, Contract Extensions and Publication of Pre-Clinical
Press spacebar to pause and continue. Press esc to stop.